DARPAÂ November 6, 2020
The ReVector program aims to maintain the health of military personnel operating in disease-endemic regions limiting exposure to mosquito-transmitted diseases.
In order to advance concept of exerting precise control over our microbiomes to provide protection from mosquito-borne diseases, DARPA has awarded ReVector Phase 1 contracts to Stanford University and Ginkgo Bioworks. They are tasked with developing precise, safe, and efficacious technologies to modulate the profile of skin-associated volatile molecules by altering the organisms that are present in the skin microbiome and/or their metabolic processes. Phase 1 of the ReVector program (18 months) will focus on modifying in vitro microbiomes, Phase 2 (18 months) will focus on modifying microbiomes of animal models, while Phase 3 (12 months) will focus on clinical tests…read more.
Credits: Centers for Disease Control and Prevention